<?xml version="1.0" encoding="utf-8" standalone="no"?>
<!DOCTYPE file
  SYSTEM 'wikixml.dtd'>
<file type="Article" date="2024-09-26T16:14:27Z" sourceCorpus="COVID-19" filename="67188057" title="ImmunityBio_COVID-19_vaccine" url="https://en.wikipedia.org/wiki/ImmunityBio_COVID-19_vaccine">
	<text>
		<segment id="id67188057">The ImmunityBio COVID-19 vaccine, codenamed hAd5, is a non replicating viral vector COVID-19 vaccine developed by the United States-based pharmaceutical company ImmunityBio.



 Manufacturing 
The BioVac Institute, a state-backed South African vaccine company, plans to use a deal it won to manufacture coronavirus vaccines.  The contract with America-based ImmunityBio Inc is currently conducting phase 1 vaccine trials in South Africa

ImmunityBio and BioVac plan to distribute the vaccines throughout South Africa and Africa.

 History 

In April 2020, a product developed by ImmunityBio was rumoured to be a potential SARS-CoV-2 coronavirus vaccine.

On 1 June 2020, the product was selected for inclusion on the Operation Warp Speed subsidy list, in order to fund monkey trials. The company &quot;hope to receive approval from the Food and Drug Administration to begin an initial safety trial in humans in June 2020.&quot;

 Clinical trials 
ImmunityBio Inc is currently conducting phase 1 vaccine trials in The United States and South Africa.

 References 


 External links 










</segment>
	</text>
</file>
